A Case of Psoriasiform Drug Eruption Induced by Imatinib Mesylate (GleevecTM).
- Author:
You In BAE
1
;
Sook Jung YUN
;
Jee Bum LEE
;
Seong Jin KIM
;
Seung Chul LEE
;
Young Ho WON
Author Information
1. Department of Dermatology, Chonnam National University Medical School, Gwangju, Korea. yhwon@chonnam.ac.kr
- Publication Type:Case Report
- Keywords:
Imatinib mesylate;
Psoriasis
- MeSH:
Benzamides;
Drug Eruptions;
Gastrointestinal Stromal Tumors;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
Mesylates;
Piperazines;
Protein-Tyrosine Kinases;
Psoriasis;
Pyrimidines;
Imatinib Mesylate
- From:Korean Journal of Dermatology
2009;47(6):722-725
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Imatinib mesylate (GleevecTM, formerly known as STI571) is an oral drug that selectively inhibits bcr-abl, c-kit and platelet-derived factor receptor (PDGFR) tyrosine kinase. It has been used for treating chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Various adverse cutaneous reactions have been reported, yet the development of psoriasis or a psoriasiform drug eruption by the drug has rarely been reported. We herein report on a case of psoriasiform drug eruption that developed after administering imatinib mesylate to treat CML.
